Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess - Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Pos

Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess

- Ex-U.S. rights realigned under amendment to

distribution agreement with Fresenius Medical Care -

- Positions Humacyte to advance discussions

with corporate partners regarding international and indication-specific rights to Symvess -

- Existing terms related to U.S. distribution

of Symvess remain unchanged

DURHAM, N.C., April 24, 2026 - Humacyte, Inc.

(Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial

scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to

its distribution agreement with Fresenius Medical Care (FME).

""We are pleased to have worked successfully with our long-time

partner and largest shareholder Fresenius Medical Care, to realign the global rights to Symvess in a manner that benefits both companies

and best enables Humacyte's planned international expansion," said Dr. Laura Niklason, CEO of Humacyte. "The restructuring

of ex-U.S. commercial rights enables us to fully advance the commercial initiatives that we previously announced in the Kingdom of Saudi

Arabia and Israel in vascular injury repair and other indications. In addition, we are now positioned to advance discussions with prospective

corporate partners regarding international and indication-specific rights to Symvess. As amended, the distribution agreement now provides

that Humacyte will have the exclusive rights to distribute Symvess outside the U.S., and FME will be entitled

to low-single-digit royalties on our net sales of Symvess outside the U.S. Existing terms related to the U.S. remain unchanged."

For uses other than the FDA approval in the extremity vascular trauma

indication, Symvess is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology

platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve

the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide

range of diseases, injuries, and chronic conditions. Humacyte's Biologics License Application for the acellular tissue engineered

vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage

clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease

(PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes,

and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate

to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation.

Humacyte's 6mm ATEV for urgent arterial repair following

extremity vascular trauma and for advanced PAD also have received

RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For

more information, visit www.Humacyte.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based

on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following

words: "may," "will," "could," "would," "should," "expect," "intend,"

"plan," "anticipate," "believe," "estimate," "predict," "project,"

"potential," "continue," "ongoing" or the negative of these terms or other comparable terminology,

although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that

may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or

implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained

in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and

our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not

limited to, our plans and ability to commercialize Symvess (including commercial initiatives in the Kingdom of Saudi Arabia and Israel)

and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market

acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our

product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient

quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives;

our plans and ability to execute product development, process development and preclinical development efforts successfully and on our

anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates

and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our

ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected

benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that

adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that

the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number

of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others,

changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive

and/or reputational factors, and other risks and uncertainties, including those described under the header "Risk Factors"

in our Annual Report on Form 10-K for the year ended December 31, 2025 filed by Humacyte with the SEC, and in future SEC filings.

Most of these factors are outside of Humacyte's control and are difficult to predict. Furthermore, if the forward-looking statements

prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements,

you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and

plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking

statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of

any date subsequent to the date of this press release.

Humacyte Investor Contact:

LifeSci Advisors LLC

Humacyte Media Contact:

Precision Strategies